Urinary Tract Infection: Pathogenesis and Outlook

Trends in Molecular Medicine

Volumn 22, Issue 11, 2016, Pages 946-957

  McLellan, Lisa K ^a   Hunstad, David A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cystitis; Escherichia coli; pyelonephritis; urinary tract infection

Indexed keywords

CATHETER INFECTION; CLINICAL FEATURE; HUMAN; IMMUNE EVASION; INFECTION COMPLICATION; MOLECULAR PATHOLOGY; NONHUMAN; RECURRENT INFECTION; REVIEW; URINARY TRACT INFECTION; ACUTE DISEASE; ANIMAL; BACTERIAL INFECTIONS; BACTERIUM; COMPLICATION; CYSTITIS; DRUG EFFECTS; FEMALE; IMMUNOLOGY; MALE; MICROBIOLOGY; PATHOLOGY; PROCEDURES; RECURRENT DISEASE; SECONDARY PREVENTION; URINARY TRACT; URINARY TRACT INFECTIONS;

ANTIINFECTIVE AGENT;

ACUTE DISEASE; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CYSTITIS; FEMALE; HUMANS; MALE; RECURRENCE; SECONDARY PREVENTION; URINARY TRACT; URINARY TRACT INFECTIONS;

EID: 84992734412     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2016.09.003     Document Type: Review

References (117)

1. 1 Harding, G.K., Ronald, A.R., The management of urinary infections: what have we learned in the past decade?. Int. J. Antimicrob. Agents 4 (1994), 83–88.
2. 2 Foxman, B., Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect. Dis. Clin. North Am. 28 (2014), 1–13.
3. 3 O'Brien, V.P., et al. Drug and vaccine development for the treatment and prevention of urinary tract infections. Microbiol. Spectr., 2016, 10.1128/microbiolspec.UTI-0013-2012 Published online February 5, 2016.
4. 4 O'Brien, V.P., et al. Are you experienced? Understanding bladder innate immunity in the context of recurrent urinary tract infection. Curr. Opin. Infect. Dis. 28 (2015), 97–105.
5. 5 Gupta, K., et al. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann. Intern. Med. 135 (2001), 41–50.
6. 6 Al-Badr, A., Al-Shaikh, G., Recurrent urinary tract infections management in women: a review. Sultan Qaboos Univ. Med. J. 13 (2013), 359–367.
7. 7 Flores-Mireles, A.L., et al. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. 13 (2015), 269–284.
8. 8 Barber, A.E., et al. Strengths and limitations of model systems for the study of urinary tract infections and related pathologies. Microbiol. Mol. Biol. Rev. 80 (2016), 351–367.
9. 9 Luthje, P., Brauner, A., Virulence factors of uropathogenic E. coli and their interaction with the host. Adv. Microb. Physiol. 65 (2014), 337–372.
10. 10 Chen, S.L., et al. Genomic diversity and fitness of E. coli strains recovered from the intestinal and urinary tracts of women with recurrent urinary tract infection. Sci. Transl. Med., 5, 2013, 184ra160.
11. 11 Yamamoto, S., et al. Genetic evidence supporting the fecal–perineal–urethral hypothesis in cystitis caused by Escherichia coli. J. Urol. 157 (1997), 1127–1129.
12. 12 Hooton, T.M., Recurrent urinary tract infection in women. Int. J. Antimicrob. Agents 17 (2001), 259–268.
13. 13 Hannan, T.J., et al. Host–pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol. Rev. 36 (2012), 616–648.
14. 14 Schwartz, D.J., et al. Population dynamics and niche distribution of uropathogenic Escherichia coli during acute and chronic urinary tract infection. Infect. Immun. 79 (2011), 4250–4259.
15. 15 Martinez, J.J., et al. Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO J. 19 (2000), 2803–2812.
16. 16 Bishop, B.L., et al. Cyclic AMP-regulated exocytosis of Escherichia coli from infected bladder epithelial cells. Nat. Med. 13 (2007), 625–630.
17. 17 Miao, Y., et al. A TRP channel senses lysosome neutralization by pathogens to trigger their expulsion. Cell 161 (2015), 1306–1319.
18. 18 Miao, Y., et al. Ubiquitination of innate immune regulator TRAF3 orchestrates expulsion of intracellular bacteria by exocyst complex. Immunity 45 (2016), 94–105.
19. 19 Anderson, G.G., et al. Intracellular bacterial biofilm-like pods in urinary tract infections. Science 301 (2003), 105–107.
20. 20 Mulvey, M.A., et al. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science 282 (1998), 1494–1497.
21. 21 Robino, L., et al. Intracellular bacteria in the pathogenesis of Escherichia coli urinary tract infection in children. Clin. Infect. Dis. 59 (2014), e158–e164.
22. 22 Rosen, D.A., et al. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med., 4, 2007, e329.
23. 23 Justice, S.S., et al. Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc. Natl. Acad. Sci. U.S.A. 101 (2004), 1333–1338.
24. 24 Mysorekar, I.U., Hultgren, S.J., Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc. Natl. Acad. Sci. U.S.A. 103 (2006), 14170–14175.
25. 25 Mulvey, M.A., et al. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect. Immun. 69 (2001), 4572–4579.
26. 26 Schilling, J.D., et al. Effect of trimethoprim–sulfamethoxazole on recurrent bacteriuria and bacterial persistence in mice infected with uropathogenic Escherichia coli. Infect. Immun. 70 (2002), 7042–7049.
27. 27 Welch, R.A., et al. Extensive mosaic structure revealed by the complete genome sequence of uropathogenic Escherichia coli. Proc. Natl. Acad. Sci. U.S.A. 99 (2002), 17020–17024.
28. 28 Hadjifrangiskou, M., et al. Transposon mutagenesis identifies uropathogenic Escherichia coli biofilm factors. J. Bacteriol. 194 (2012), 6195–6205.
29. 29 Nicholson, T.F., et al. OmpA of uropathogenic Escherichia coli promotes postinvasion pathogenesis of cystitis. Infect. Immun. 77 (2009), 5245–5251.
30. 30 Kulesus, R.R., et al. Impact of the RNA chaperone Hfq on the fitness and virulence potential of uropathogenic Escherichia coli. Infect. Immun. 76 (2008), 3019–3026.
31. 31 Alteri, C.J., et al. Preferential use of central metabolism in vivo reveals a nutritional basis for polymicrobial infection. PLoS Pathog., 11, 2015, e1004601.
32. 32 Subashchandrabose, S., et al. Host-specific induction of Escherichia coli fitness genes during human urinary tract infection. Proc. Natl. Acad. Sci. U.S.A. 111 (2014), 18327–18332.
33. 33 Alteri, C.J., et al. Mucosal immunization with iron receptor antigens protects against urinary tract infection. PLoS Pathog., 5, 2009, e1000586.
34. 34 Alteri, C.J., et al. Fitness of Escherichia coli during urinary tract infection requires gluconeogenesis and the TCA cycle. PLoS Pathog., 5, 2009, e1000448.
35. 35 Alteri, C.J., Mobley, H.L., Metabolism and fitness of urinary tract pathogens. Microbiol. Spectr., 2015, 10.1128/microbiolspec.MBP-0016-2015 Published online June 18, 2015.
36. 36 Justice, S.S., et al. Maturation of intracellular Escherichia coli communities requires SurA. Infect. Immun. 74 (2006), 4793–4800.
37. 37 Conover, M.S., et al. Metabolic requirements of Escherichia coli in intracellular bacterial communities during urinary tract infection pathogenesis. MBio 7 (2016), e00104–e116.
38. 38 Ragnarsdottir, B., et al. Genetics of innate immunity and UTI susceptibility. Nat. Rev. Urol. 8 (2011), 449–468.
39. 39 Olson, P.D., Hunstad, D.A., Subversion of host innate immunity by uropathogenic Escherichia coli. Pathogens, 5, 2016, 2.
40. 40 Haraoka, M., et al. Neutrophil recruitment and resistance to urinary tract infection. J. Infect. Dis. 180 (1999), 1220–1229.
41. 41 Artifoni, L., et al. Interleukin-8 and CXCR1 receptor functional polymorphisms and susceptibility to acute pyelonephritis. J. Urol. 177 (2007), 1102–1106.
42. 42 Ingersoll, M.A., et al. G-CSF induction early in uropathogenic Escherichia coli infection of the urinary tract modulates host immunity. Cell. Microbiol. 10 (2008), 2568–2578.
43. 43 Svensson, M., et al. Effects of epithelial and neutrophil CXCR2 on innate immunity and resistance to kidney infection. Kidney Int. 74 (2008), 81–90.
44. 44 Sarkar, S., et al. Role of capsule and O antigen in the virulence of uropathogenic Escherichia coli. PLoS ONE, 9, 2014, e94786.
45. 45 Weichhart, T., et al. Current concepts of molecular defence mechanisms operative during urinary tract infection. Eur. J. Clin. Invest. 38:Suppl. 2 (2008), 29–38.
46. 46 Danka, E.S., Hunstad, D.A., Cathelicidin augments epithelial receptivity and pathogenesis in experimental Escherichia coli cystitis. J. Infect. Dis. 211 (2015), 1164–1173.
47. 47 Durr, U.H., et al. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim. Biophys. Acta 1758 (2006), 1408–1425.
48. 48 Nielsen, K.L., et al. Role of urinary cathelicidin LL-37 and human β-defensin 1 in uncomplicated Escherichia coli urinary tract infections. Infect. Immun. 82 (2014), 1572–1578.
49. 49 Becknell, B., et al. Expression and antimicrobial function of β-defensin 1 in the lower urinary tract. PLoS ONE, 8, 2013, e77714.
50. 50 Spencer, J.D., et al. Ribonuclease 7, an antimicrobial peptide upregulated during infection, contributes to microbial defense of the human urinary tract. Kidney Int. 83 (2013), 615–625.
51. 51 Steigedal, M., et al. Lipocalin 2 imparts selective pressure on bacterial growth in the bladder and is elevated in women with urinary tract infection. J. Immunol. 193 (2014), 6081–6089.
52. 52 Lin, A.E., et al. Role of hypoxia inducible factor-1α in innate defense against uropathogenic Escherichia coli infection. PLoS Pathog., 11, 2015, e1004818.
53. 53 Jaillon, S., et al. The humoral pattern recognition molecule PTX3 is a key component of innate immunity against urinary tract infection. Immunity 40 (2014), 621–632.
54. 54 Justice, S.S., et al. Filamentation by Escherichia coli subverts innate defenses during urinary tract infection. Proc. Natl. Acad. Sci. U.S.A. 103 (2006), 19884–19889.
55. 55 Lau, M.E., et al. YbcL of uropathogenic Escherichia coli suppresses transepithelial neutrophil migration. Infect. Immun. 80 (2012), 4123–4132.
56. 56 Loughman, J.A., Hunstad, D.A., Attenuation of human neutrophil migration and function by uropathogenic bacteria. Microbes Infect. 13 (2011), 555–565.
57. 57 Lau, M.E., et al. Bacterial lysis liberates the neutrophil migration suppressor YbcL from the periplasm of uropathogenic Escherichia coli. Infect. Immun. 82 (2014), 4921–4930.
58. 58 Loughman, J.A., Hunstad, D.A., Induction of indoleamine 2,3-dioxygenase by uropathogenic bacteria attenuates innate responses to epithelial infection. J. Infect. Dis. 205 (2012), 1830–1839.
59. 59 Loughman, J.A., et al. Local generation of kynurenines mediates inhibition of neutrophil chemotaxis by uropathogenic Escherichia coli. Infect. Immun. 84 (2016), 1176–1183.
60. 60 Waldhuber, A., et al. Uropathogenic Escherichia coli strain CFT073 disrupts NLRP3 inflammasome activation. J. Clin. Invest. 126 (2016), 2425–2436.
61. 61 Cirl, C., et al. Subversion of Toll-like receptor signaling by a unique family of bacterial Toll/interleukin-1 receptor domain-containing proteins. Nat. Med. 14 (2008), 399–406.
62. 62 Hannan, T.J., et al. Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog., 6, 2010, e1001042.
63. 63 Schwartz, D.J., et al. Uropathogenic Escherichia coli superinfection enhances the severity of mouse bladder infection. PLoS Pathog., 11, 2015, e1004599.
64. 64 Peck, A., Mellins, E.D., Precarious balance: Th17 cells in host defense. Infect. Immun. 78 (2010), 32–38.
65. 65 Sivick, K.E., et al. The innate immune response to uropathogenic Escherichia coli involves IL-17A in a murine model of urinary tract infection. J. Immunol. 184 (2010), 2065–2075.
66. 66 Sivick, K.E., Mobley, H.L., Waging war against uropathogenic Escherichia coli: winning back the urinary tract. Infect. Immun. 78 (2010), 568–585.
67. 67 Kantele, A., et al. Antibody-secreting cells in acute urinary tract infection as indicators of local immune response. J. Infect. Dis. 169 (1994), 1023–1028.
68. 68 Kudinha, T., et al. Escherichia coli sequence type 131 as a prominent cause of antibiotic resistance among urinary Escherichia coli isolates from reproductive-age women. J. Clin. Microbiol. 51 (2013), 3270–3276.
69. 69 Spellberg, B., et al. Novel approaches are needed to develop tomorrow's antibacterial therapies. Am. J. Respir. Crit. Care Med. 191 (2015), 135–140.
70. 70 Hoberman, A., et al. Antimicrobial prophylaxis for children with vesicoureteral reflux. N. Engl. J. Med. 370 (2014), 2367–2376.
71. 71 Goneau, L.W., et al. Subinhibitory antibiotic therapy alters recurrent urinary tract infection pathogenesis through modulation of bacterial virulence and host immunity. MBio., 6, 2015 e00356-15.
72. 72 Greene, S.E., et al. Pilicide ec240 disrupts virulence circuits in uropathogenic Escherichia coli. mBio, 5, 2014, e02038.
73. 73 Dang, H.T., et al. Syntheses and biological evaluation of 2-amino-3-acyl-tetrahydrobenzothiophene derivatives; antibacterial agents with antivirulence activity. Org. Biomol. Chem. 12 (2014), 1942–1956.
74. 74 Han, Z., et al. Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides. J. Med. Chem. 55 (2012), 3945–3959.
75. 75 Cusumano, C.K., et al. Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci. Transl. Med., 3, 2011, 109ra115.
76. 76 Totsika, M., et al. A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug-resistant uropathogenic Escherichia coli ST131. J. Infect. Dis. 208 (2013), 921–928.
77. 77 Guiton, P.S., et al. Combinatorial small-molecule therapy prevents uropathogenic Escherichia coli catheter-associated urinary tract infections in mice. Antimicrob. Agents Chemother. 56 (2012), 4738–4745.
78. 78 Jarvis, C., et al. Antivirulence isoquinolone mannosides: optimization of the biaryl aglycone for FimH lectin binding affinity and efficacy in the treatment of chronic UTI. ChemMedChem 11 (2016), 367–373.
79. 79 Mühlen, S., Dersch, P., Anti-virulence strategies to target bacterial infections. Curr. Top. Microbiol. Immunol., 2016, 10.1007/82_2015_490 Published online March 5, 2016.
80. 80 Chorell, E., et al. Design and synthesis of fluorescent pilicides and curlicides: bioactive tools to study bacterial virulence mechanisms. Chemistry 18 (2012), 4522–4532.
81. 81 Volkan, E., et al. Molecular basis of usher pore gating in Escherichia coli pilus biogenesis. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), 20741–20746.
82. 82 Geibel, S., et al. Structural and energetic basis of folded-protein transport by the FimD usher. Nature 496 (2013), 243–246.
83. 83 Sarowar, S., et al. The Escherichia coli P and type 1 pilus assembly chaperones PapD and FimC are monomeric in solution. J. Bacteriol. 198 (2016), 2360–2369.
84. 84 Hospenthal, M.K., et al. Structure of a chaperone–usher pilus reveals the molecular basis of rod uncoiling. Cell 164 (2016), 269–278.
85. A from E. coli pili to emulate the bacterial mode of epithelial internalization. J. Am. Chem. Soc. 134 (2012), 3938–3941.
86. 86 Lim, Y.H., et al. Preparation and in vitro antimicrobial activity of silver-bearing degradable polymeric nanoparticles of polyphosphoester-block-poly(L-lactide). ACS Nano 9 (2015), 1995–2008.
87. 87 Brumbaugh, A.R., et al. Immunization with the yersiniabactin receptor, FyuA, protects against pyelonephritis in a murine model of urinary tract infection. Infect. Immun. 81 (2013), 3309–3316.
88. 88 Nesta, B., et al. FdeC, a novel broadly conserved Escherichia coli adhesin eliciting protection against urinary tract infections. MBio, 3, 2012 2e00010-12.
89. 89 Langermann, S., et al. Prevention of mucosal Escherichia coli infection by FimH–adhesin-based systemic vaccination. Science 276 (1997), 607–611.
90. 90 Spaulding, C.N., Hultgren, S.J., Adhesive pili in UTI pathogenesis and drug development. Pathogens, 2016, 10.3390/pathogens5010030 Published online March 15, 2016.
91. 91 Hannan, T.J., et al. Inhibition of cyclooxygenase-2 prevents chronic and recurrent cystitis. EBioMedicine 1 (2014), 46–57.
92. 92 Gágyor, I., et al. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection: randomised controlled trial. BMJ, 351, 2015, h6544.
93. 93 Wagers, P.O., et al. Imidazolium salts as small-molecule urinary bladder exfoliants in a murine model. Antimicrob. Agents Chemother. 59 (2015), 5494–5502.
94. 94 Blango, M.G., et al. Forced resurgence and targeting of intracellular uropathogenic Escherichia coli reservoirs. PLoS ONE, 9, 2014, e93327.
95. 95 Brubaker, L., Wolfe, A., The urinary microbiota: a paradigm shift for bladder disorders?. Curr. Opin. Obstet. Gynecol. 28 (2016), 407–412.
96. 96 Hilt, E.E., et al. Urine is not sterile: use of enhanced urine culture techniques to detect resident bacterial flora in the adult female bladder. J. Clin. Microbiol. 52 (2014), 871–876.
97. 97 Nienhouse, V., et al. Interplay between bladder microbiota and urinary antimicrobial peptides: mechanisms for human urinary tract infection risk and symptom severity. PLoS ONE, 9, 2014, e114185.
98. 98 Pearce, M.M., et al. The female urinary microbiome in urgency urinary incontinence. Am. J. Obstet. Gynecol. 213 (2015), 347.e1–347.e11.
99. 99 Thomas-White, K.J., et al. Evaluation of the urinary microbiota of women with uncomplicated stress urinary incontinence. Am. J. Obstet. Gynecol., 2016, 10.1016/j.ajog.2016.07.049 Published online August 4, 2016.
100. 100 Hung, C.S., et al. A murine model of urinary tract infection. Nat. Protoc. 4 (2009), 1230–1243.
101. 101 Hannan, T.J., Hunstad, D.A., A murine model for Escherichia coli urinary tract infection. Methods Mol. Biol. 1333 (2016), 159–175.
102. 102 Lo, E., et al. Strategies to prevent catheter-associated urinary tract infections in acute care hospitals: 2014 update. Infect. Control Hosp. Epidemiol. 35 (2014), 464–479.
103. 103 Foxman, B., The epidemiology of urinary tract infection. Nat. Rev. Urol. 7 (2010), 653–660.
104. 104 Guiton, P.S., et al. Enterococcal biofilm formation and virulence in an optimized murine model of foreign body-associated urinary tract infections. Infect. Immun. 78 (2010), 4166–4175.
105. 105 Flores-Mireles, A.L., et al. EbpA vaccine antibodies block binding of Enterococcus faecalis to fibrinogen to prevent catheter-associated bladder infection in mice. Sci. Transl. Med., 6, 2014, 254ra127.
106. 106 Flores-Mireles, A.L., et al. Fibrinogen release and deposition on urinary catheters placed during urological procedures. J. Urol. 196 (2016), 416–421.
107. 107 Conover, M.S., et al. Establishment and characterization of UTI and CAUTI in a mouse model. J. Vis. Exp., 2015, 2015, e52892.
108. 108 Murawski, I.J., et al. Vesico-ureteric reflux: using mouse models to understand a common congenital urinary tract defect. Pediatr. Nephrol. 26 (2011), 1513–1522.
109. 109 Foxman, B., Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis. Mon. 49 (2003), 53–70.
110. 110 Foxman, B., et al. Acute pyelonephritis in US hospitals in 1997: hospitalization and in-hospital mortality. Ann. Epidemiol. 13 (2003), 144–150.
111. 111 Boehm, B.J., et al. Acute bacterial inflammation of the mouse prostate. Prostate 72 (2012), 307–317.
112. 112 Rudick, C.N., et al. Uropathogenic Escherichia coli induces chronic pelvic pain. Infect. Immun. 79 (2011), 628–635.
113. 113 Olson, P.D., et al. Androgens enhance male urinary tract infection severity in a new model. J. Am. Soc. Nephrol. 27 (2016), 1625–1634.
114. 114 Roberts, K.B., Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics 128 (2011), 595–610.
115. 115 Demarco, M.L., Burnham, C.A., Diafiltration MALDI-TOF mass spectrometry method for culture-independent detection and identification of pathogens directly from urine specimens. Am. J. Clin. Pathol. 141 (2014), 204–212.
116. 116 Johnson, J.R., et al. Rapid and specific detection, molecular epidemiology, and experimental virulence of the O16 subgroup within Escherichia coli sequence type 131. J. Clin. Microbiol. 52 (2014), 1358–1365.
117. 117 Tchesnokova, V.L., et al. Rapid identification of rectal multidrug-resistant Escherichia coli before transrectal prostate biopsy. Urology 86 (2015), 1200–1205.